Greetings my butt-ugly balding brothers.
A (bald) heads-up on Replicel for tonight. I still have faith in this company which is why I continue to track it.
Its a 30 min audio recording of Replicel’s presentation at the “Rodman & Renshaw Annual Global Investment Conference” at the Waldorf Astoria hotel in New York. The presentation was given by Replicel’s CEO David Hall.
While you’re listening to the recording, there are slides to the right you can click through. Click ‘Next’ to follow along.
The first half of the recording is what we all already know about Replicel’s methods. The second part goes into depth regarding their Phase II trials.
Go here, fill in some (BS) information (first name, last name, email…etc) and you will be taken to the presentation :
Some notes I jotted down :
Phase II - Efficacy
- Diff doses, diff freq
3 different doses - 250K to 1 million cells
vs 5 & 10 million cells in Phase I
Treatment group in Phase II
A - Day 1 with 3 different doses
B - Day 1 and at 3 months
Placebo - Single & Double injection of Placebo
252 treated sites with 108 patients - will be conducted at Sherita (sp?) University in Berlin, Germany
Cost of this trial = 5 million dollars
2 value development pathways
Existing injector device - injects and lays cells on the way out
New upcoming injector device - pen like gadget
19 cell markers, 4 in testing